Spondyloarthritis & psoriatic arthritis
Intensive biological DMARD-first strategy versus standard step-up care in psoriatic arthritis (STAMP): 1-year results from a multicentre, open-label, randomised controlled trial comparing two treat-to-target strategies
Primary result · ACR50 responseResult — go to the resultRelative risk 1.19 95% CI 0.75–1.88Authors' conclusion
Early use of intensive treatment with secukinumab in a treat-to-target strategy did not result in statistically superior outcomes compared with a conventional step-up treat-to-target approach.
Study context
- Population
- Adults with newly diagnosed PsA fulfilling CASPAR criteria, ≥2 swollen joints, DMARD-naive; 11 general hospitals and one academic hospital in the Netherlands130 screened
- Participants
- 120 adults
- Comparison
- Early secukinumab plus MTX vs standard of care step-up MTX
- Early secukinumabn = 60
- Standard of caren = 60reference
- Primary endpoint
- Proportion of patients with an ACR50 response (ITT population)
- Follow-up
- 6 months
Methodological detailsmulticentre, open-label, treat-to-target strategies
- Multicentre
- Open-label
- Treat-to-target strategies
Primary result
ACR50 response · month 6
Relative risk
1.19
95% CI 0.75–1.88
P = 0.45
Events by treatment group
Early secukinumabvs Standard of care
RR 1.19 (95% CI 0.75–1.88); P = 0.45
As reported in the abstract
Further findings
- No deaths occurred in either group
Safety
Adverse events
Serious adverse events
Original publication
Intensive biological DMARD-first strategy versus standard step-up care in psoriatic arthritis (STAMP): 1-year results from a multicentre, open-label, randomised controlled trial comparing two treat-to-target strategies. Lancet Rheumatol. Published 20 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →